INTRODUCTION: Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional guidelines and product labels may contribute. PATIENTS AND METHODS: We analysed SITS-International registry patients enrolled January 2010 through June 2016. We grouped sites into organisational tertiles by number of patients arriving ≤2.5 h and treated ≤3 h, percentage arriving ≤2.5 h and treated ≤3 h, and numbers treated ≤3 h. We assigned scores of 1-3 (lower/middle/upper) per variable and 2 for onsite thrombectomy. We classified sites as lower efficiency (summed scores 3-5), medium efficiency (6-8) or higher efficiency (9-11). Sites were also grouped by adherence with European product label and ESO guideline: 'label adherent' (>95% on-label), 'guideline adherent' (≥5% off-label, ≥95% on-guideline) or 'guideline non-adherent' (>5% off-guideline). We cross-tabulated site-efficiency and adherence. We estimated the potential benefit of universally selecting by ESO guidance, using onset-to-treatment time-specific numbers needed to treat for day 90 mRS 0-1. RESULTS: A total of 56,689 patients at 597 sites were included: 163 sites were higher efficiency, 204 medium efficiency and 230 lower efficiency. Fifty-six sites were 'label adherent', 204 'guideline adherent' and 337 'guideline non-adherent'. There were strong associations between site-efficiency and adherence (P < 0.001). Almost all 'label adherent' sites (55, 98%) were lower efficiency. If all patients were treated by ESO guidelines, an additional 17,031 would receive alteplase, which translates into 1922 more patients with favourable three-month outcomes. DISCUSSION: Adherence with product labels is highest in lower efficiency sites. Closer alignment with professional guidelines would increase patients treated and favourable outcomes. CONCLUSION: Product labels should be revised to allow treatment of patients ≤4.5 h from onset and aged ≥80 years.

Department of Clinical Neuroscience Karolinska Institute Stockholm Sweden

Department of Neurology Karolinska University Hospital Stockholm Sweden

Department of Neurology University of Heidelberg Heidelberg Germany

Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK

Institute of Neuroscience and Psychology University of Glasgow Glasgow UK

International Clinical Research Centre Neurology Department St Anne's Hospital and Masaryk University Brno Czech Republic

See more in PubMed

Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450–1458. PubMed

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1588. PubMed

Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025. PubMed

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245–1251. PubMed

Wardlaw JM, Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 12: CD000213. PubMed

Meretoja A, Tatlisumak T. Thrombolytic therapy in acute ischemic stroke – basic concepts. Curr Vasc Pharmacol 2006; 4: 31–44. PubMed

Meretoja A, Tatlisumak T. Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? CNS Drugs 2008; 22: 619–629. PubMed

Schumacher HC, Bateman BT, Boden-Albala B, et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med 2007; 50: 99–107. PubMed

Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47: 581–641. PubMed

Gumbinger C, Reuter B, Stock C, et al. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ 2014; 348: g3429. PubMed PMC

Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–1329. PubMed

Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303–1309. PubMed

Lees KR, Bluhmki E, Kummer von R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695–1703. PubMed

Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341: c6046–c6046. PubMed PMC

Karliński M, Kobayashi A, Litwin T, et al. Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland. Neurol Neurochir Pol 2014; 46: 3–14. PubMed

Ford GA, Ahmed N, Azevedo E, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41: 2568–2574. PubMed

Meseguer E, Labreuche J, Olivot JM, et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing 2008; 37: 107–111. PubMed

Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or =80 versus <80 years of age – a systematic review across cohort studies. Age Ageing 2006; 35: 572–580. PubMed

European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507. PubMed

ESO Guideline Update (Abstract) – January 2009, European Stroke Organisation. www.congrex-switzerland.com/fileadmin/files/2013/eso-stroke/pdf/ESO_Guideline_Update_Jan_2009.pdf (accessed 28 August 2017).

Jauch EC, Saver JL, Adams HP, Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947. PubMed

Cappellari M, Moretto G, Micheletti N, et al. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke. J Thromb Thrombolysis 2013; 37: 549–556. PubMed

Scheitz JF, Abdul-Rahim AH, MacIsaac RL, et al. Clinical selection strategies to identify ischemic stroke patients with large anterior vessel occlusion. Stroke 2017; 48: 290–297. PubMed

Tsivgoulis G, Safouris A, Alexandrov AV. Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions. Expert Opin Drug Saf 2015; 14: 845–864. PubMed

Frank B, Grotta JC, Alexandrov AV, et al. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013; 44: 727–733. PubMed

Hacke W, Lyden P, Emberson J, et al. Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. Int J Stroke. Epub ahead of print 2017. doi: 10.1177/1747493017744464. PubMed

Nomani AZ, Nabi S, Badshah M, et al. Review of acute ischaemic stroke in Pakistan: progress in management and future perspectives. Stroke Vasc Neurol 2017; 2: 30–39. PubMed PMC

Anani N, Mazya MV, Bill O, et al. Changes in European Label and guideline adherence after updated recommendations for stroke thrombolysis: results from the safe implementation of treatments in stroke registry. Circ Cardiovasc Qual Outcomes 2015; 8: S155–S162. PubMed

Wiedmann S, Norrving B, Nowe T, et al. Variations in quality indicators of acute stroke care in 6 European countries. Stroke 2012; 43: 458–463. PubMed